At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,747 enrolled
Drug / intervention
Novel endpoint determinationother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time
In Brief
An observational study evaluating Novel endpoint determination for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 2,747 participants across 44 sites in 12 countries.
Detailed Summary
This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesBulgaria, Canada, Czechia, Denmark, Netherlands, New Zealand, Norway, Slovenia, Spain, Ukraine, United Kingdom, United States
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
First PostedFeb 2006
Primary CompletionFeb 2010
TodayJul 2026
First PostedFeb 16, 2006
Enrollment StartDec 1, 2005
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 20.4 years ago
Interventions
Novel endpoint determinationother
Novel endpoint determination